Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle.

Chiu YL, Greene WC.

J Biol Chem. 2006 Mar 31;281(13):8309-12. Epub 2005 Dec 30. Review.

2.

Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.

Izumi T, Shirakawa K, Takaori-Kondo A.

Mini Rev Med Chem. 2008 Mar;8(3):231-8. Review.

PMID:
18336343
3.

Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3.

Ohsugi T, Koito A.

J Virol Methods. 2007 Jan;139(1):93-6. Epub 2006 Nov 22.

PMID:
17123636
4.
5.

Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.

Bonvin M, Greeve J.

Curr Opin Infect Dis. 2008 Jun;21(3):298-303. doi: 10.1097/QCO.0b013e3282fe1bb2. Review.

PMID:
18448976
6.

Interaction between HIV-1 and APOBEC3 sub-family of proteins.

Arriaga ME, Carr J, Li P, Wang B, Saksena NK.

Curr HIV Res. 2006 Oct;4(4):401-9. Review.

PMID:
17073615
7.

APOBEC3 proteins and porcine endogenous retroviruses.

Dörrschuck E, Münk C, Tönjes RR.

Transplant Proc. 2008 May;40(4):959-61. doi: 10.1016/j.transproceed.2008.03.032.

PMID:
18555089
8.

Directed DNA deamination by AID/APOBEC3 in immunity.

Macduff DA, Harris RS.

Curr Biol. 2006 Mar 21;16(6):R186-9. No abstract available.

9.

Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains.

Hakata Y, Landau NR.

J Biol Chem. 2006 Dec 1;281(48):36624-31. Epub 2006 Oct 4.

10.

A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.

Zhou T, Han Y, Dang Y, Wang X, Zheng YH.

Retrovirology. 2009 Apr 3;6:31. doi: 10.1186/1742-4690-6-31.

11.

Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.

Huthoff H, Towers GJ.

Trends Microbiol. 2008 Dec;16(12):612-9. doi: 10.1016/j.tim.2008.08.013. Epub 2008 Oct 29. Review.

12.
13.
14.

The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.

Chiu YL, Greene WC.

Annu Rev Immunol. 2008;26:317-53. doi: 10.1146/annurev.immunol.26.021607.090350. Review.

PMID:
18304004
15.

Host restriction of murine gammaherpesvirus 68 replication by human APOBEC3 cytidine deaminases but not murine APOBEC3.

Minkah N, Chavez K, Shah P, Maccarthy T, Chen H, Landau N, Krug LT.

Virology. 2014 Apr;454-455:215-26. doi: 10.1016/j.virol.2014.02.022. Epub 2014 Mar 13.

16.

Intrinsic immunity: a front-line defense against viral attack.

Bieniasz PD.

Nat Immunol. 2004 Nov;5(11):1109-15. Review.

PMID:
15496950
17.

Restriction of feline retroviruses: lessons from cat APOBEC3 cytidine deaminases and TRIM5alpha proteins.

Münk C, Hechler T, Chareza S, Löchelt M.

Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):14-24. doi: 10.1016/j.vetimm.2009.10.004. Epub 2009 Oct 9. Review.

PMID:
19896724
18.

Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.

Sakuma R, Mael AA, Ikeda Y.

J Virol. 2007 Sep;81(18):10201-6. Epub 2007 Jul 3.

19.

Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations.

Duggal NK, Fu W, Akey JM, Emerman M.

Virology. 2013 Sep 1;443(2):329-37. doi: 10.1016/j.virol.2013.05.016. Epub 2013 Jun 10.

20.

Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism.

Suspène R, Aynaud MM, Guétard D, Henry M, Eckhoff G, Marchio A, Pineau P, Dejean A, Vartanian JP, Wain-Hobson S.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4858-63. doi: 10.1073/pnas.1009687108. Epub 2011 Mar 2.

Supplemental Content

Support Center